KD
Knott David M Jr
13F filer · CIK 0001892770Reported Aug 12, 2026
Net seller this quarter
13F portfolio value$189MU.S. long equity reported on 13F
Positions769 new · 11 closed
Net flow last quarter-$3.86MBuys minus sells
Top 10 positions weight62.8%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 12, 202676 positions | |||||
| $32.3M | 17.07% | Not reported | Not reported | Q4 2021 | |
| $26.6M | 14.07% | 0.04% | Not reported | Q4 2021 | |
| $9.56M | 5.05% | 0.49% | +3.6% | Q1 2024 | |
| $8.4M | 4.44% | 0.61% | Not reported | Q4 2023 | |
| $8.37M | 4.42% | 0.16% | +4.7% | Q3 2023 | |
| $7.72M | 4.08% | 0.10% | Not reported | Q3 2023 | |
| $6.92M | 3.66% | 0.05% | +3.2% | Q1 2022 | |
| $6.66M | 3.52% | 0.35% | Not reported | Q4 2021 | |
| $6.38M | 3.37% | 0.07% | +1.5% | Q2 2023 | |
| $5.92M | 3.13% | 0.00% | -7.1% | Q4 2021 | |
| $4.3M | 2.27% | 0.06% | +6.8% | Q1 2025 | |
| $3.67M | 1.94% | 0.04% | -25.7% | Q4 2021 | |
| $3.58M | 1.89% | 2.83% | New | Q2 2026 | |
| $3.53M | 1.86% | 0.16% | +2.2% | Q4 2025 | |
| $3.32M | 1.76% | 0.16% | Not reported | Q4 2024 | |
| $3.12M | 1.65% | 0.42% | +2.7% | Q4 2021 | |
| $2.5M | 1.32% | 0.06% | Not reported | Q1 2025 | |
| $2.45M | 1.29% | 0.72% | +5.7% | Q4 2024 | |
| $1.92M | 1.02% | 0.38% | Not reported | Q3 2025 | |
| $1.69M | 0.89% | 0.05% | Not reported | Q4 2021 | |
| $1.61M | 0.85% | 0.01% | +50.0% | Q3 2022 | |
| $1.44M | 0.76% | 0.10% | Not reported | Q1 2025 | |
| $1.38M | 0.73% | 2.70% | Not reported | Q4 2021 | |
| $1.34M | 0.71% | 0.11% | +27.1% | Q3 2022 | |
| $1.27M | 0.67% | 0.04% | +15.1% | Q1 2025 | |
| $1.26M | 0.67% | 0.11% | +185.9% | Q1 2026 | |
| $1.25M | 0.66% | 0.00% | Not reported | Q4 2021 | |
| $1.12M | 0.59% | 0.04% | Not reported | Q1 2025 | |
| $1.09M | 0.58% | 0.42% | Not reported | Q2 2025 | |
| $1.08M | 0.57% | 0.73% | New | Q2 2026 | |
| $1.06M | 0.56% | 0.71% | +14.7% | Q4 2025 | |
| $864K | 0.46% | 0.00% | Not reported | Q3 2025 | |
| $779K | 0.41% | 0.00% | Not reported | Q4 2021 | |
| $722K | 0.38% | 0.00% | Not reported | Q4 2021 | |
| $664K | 0.35% | 0.00% | Not reported | Q4 2021 | |
| $624K | 0.33% | 0.59% | +4.8% | Q3 2025 | |
| $602K | 0.32% | 0.00% | Not reported | Q1 2023 | |
| $597K | 0.32% | 0.00% | Not reported | Q4 2021 | |
| $592K | 0.31% | 0.17% | +49.0% | Q1 2026 | |
| $579K | 0.31% | 0.06% | Not reported | Q2 2024 | |
| $562K | 0.30% | 0.05% | +19.2% | Q1 2025 | |
| $453K | 0.24% | 0.00% | New | Q2 2026 | |
| $421K | 0.22% | 0.05% | New | Q2 2026 | |
| $388K | 0.21% | 0.03% | New | Q2 2026 | |
| $387K | 0.20% | 0.13% | New | Q2 2026 | |
| $314K | 0.17% | 0.01% | New | Q2 2026 | |
| $309K | 0.16% | 0.00% | Not reported | Q4 2021 | |
| $268K | 0.14% | 0.00% | Not reported | Q2 2022 | |
| $263K | 0.14% | 0.00% | Not reported | Q4 2021 | |
| $256K | 0.14% | 0.00% | Not reported | Q2 2022 | |
| Q1 2026Reported May 14, 202678 positions | |||||
| $26.2M | 15.61% | Not reported | Not reported | Q4 2021 | |
| $25.1M | 14.92% | 0.04% | Not reported | Q4 2021 | |
| $9.86M | 5.87% | 0.48% | +1.7% | Q1 2024 | |
| $6.68M | 3.98% | 0.05% | +5.9% | Q1 2022 | |
| $6.64M | 3.95% | 0.10% | -13.7% | Q3 2023 | |
| $6.15M | 3.66% | 0.61% | +9.3% | Q4 2023 | |
| $5.73M | 3.41% | 0.00% | Not reported | Q4 2021 | |
| $5.62M | 3.34% | 0.37% | Not reported | Q4 2021 | |
| $4.24M | 2.53% | 0.07% | +26.3% | Q2 2023 | |
| $4.18M | 2.49% | 0.15% | -24.4% | Q3 2023 | |
| $4M | 2.38% | 0.06% | +2.0% | Q1 2025 | |
| $3.54M | 2.11% | 0.18% | +24.8% | Q4 2024 | |
| $3.15M | 1.87% | 0.16% | +417.0% | Q4 2025 | |
| $3.06M | 1.82% | 0.42% | Not reported | Q4 2021 | |
| $2.99M | 1.78% | 0.06% | +100.0% | Q4 2021 | |
| CPCPRXCatalyst Pharmaceuticals, Inc. | $2.97M | 1.77% | 0.10% | -36.5% | Q4 2023 |
| AACLXArcellx, Inc. | $2.23M | 1.33% | 0.03% | -24.4% | Q1 2023 |
| $1.8M | 1.07% | 0.05% | Not reported | Q4 2021 | |
| $1.75M | 1.04% | 0.06% | -33.0% | Q1 2025 | |
| $1.68M | 1.00% | 2.70% | Not reported | Q4 2021 | |
| $1.68M | 1.00% | 0.68% | +22.7% | Q4 2024 | |
| $1.56M | 0.93% | 0.02% | -30.5% | Q1 2024 | |
| CPCNTACentessa Pharmaceuticals PLC | $1.55M | 0.92% | 0.03% | +875.0% | Q4 2025 |
| $1.47M | 0.87% | 0.10% | Not reported | Q1 2025 | |
| $1.24M | 0.74% | 0.08% | Not reported | Q3 2022 | |
| $1.2M | 0.72% | 0.00% | -28.9% | Q4 2021 | |
| $1.13M | 0.67% | 0.38% | +8.8% | Q3 2025 | |
| $1.08M | 0.64% | 0.43% | +1.5% | Q2 2025 | |
| $1.05M | 0.62% | 0.01% | Not reported | Q3 2022 | |
| $1.05M | 0.62% | 0.04% | Not reported | Q1 2025 | |
| $1.02M | 0.60% | 0.62% | +93.9% | Q4 2025 | |
| $908K | 0.54% | 0.00% | Not reported | Q4 2021 | |
| $826K | 0.49% | 0.00% | -38.1% | Q4 2021 | |
| $819K | 0.49% | 0.00% | Not reported | Q4 2021 | |
| $733K | 0.44% | 0.00% | -33.3% | Q3 2025 | |
| $693K | 0.41% | 0.03% | +65.3% | Q1 2025 | |
| $633K | 0.38% | 0.00% | Not reported | Q4 2021 | |
| $592K | 0.35% | 0.00% | Not reported | Q4 2021 | |
| $551K | 0.33% | 0.12% | New | Q1 2026 | |
| $542K | 0.32% | 0.03% | Not reported | Q4 2021 | |
| $519K | 0.31% | 0.00% | Not reported | Q1 2023 | |
| $443K | 0.26% | 0.63% | +9.3% | Q3 2025 | |
| $429K | 0.26% | 0.06% | +34.6% | Q2 2024 | |
| $408K | 0.24% | 0.15% | Not reported | Q1 2023 | |
| $344K | 0.20% | 0.04% | New | Q1 2026 | |
| $339K | 0.20% | 0.05% | -71.0% | Q1 2025 | |
| $309K | 0.18% | 0.11% | -37.2% | Q2 2025 | |
| $290K | 0.17% | 0.02% | -55.6% | Q1 2025 | |
| $258K | 0.15% | Not reported | New | Q1 2026 | |
| $232K | 0.14% | 0.00% | Not reported | Q4 2021 | |
| Q4 2025Reported Feb 12, 202681 positions | |||||
| $44M | 20.38% | 2.55% | -21.6% | Q4 2021 | |
| $32.6M | 15.08% | 0.04% | Not reported | Q4 2021 | |
| $28.7M | 13.28% | Not reported | -18.5% | Q4 2021 | |
| $8.72M | 4.04% | 0.47% | -3.0% | Q1 2024 | |
| $7.61M | 3.53% | 0.58% | -4.4% | Q4 2023 | |
| $7.11M | 3.29% | 0.20% | -28.5% | Q3 2023 | |
| $6.5M | 3.01% | 0.04% | Not reported | Q1 2022 | |
| $6.38M | 2.95% | 0.12% | -12.1% | Q3 2023 | |
| $6.28M | 2.91% | 0.00% | -4.4% | Q4 2021 | |
| $4.51M | 2.09% | 0.14% | +24.4% | Q4 2024 | |
| CPCPRXCatalyst Pharmaceuticals, Inc. | $4.41M | 2.04% | 0.15% | Not reported | Q4 2023 |
| $3.62M | 1.68% | 0.06% | Not reported | Q1 2025 | |
| $2.89M | 1.34% | 0.10% | +27.4% | Q1 2025 | |
| $2.66M | 1.23% | 0.06% | +392.2% | Q2 2023 | |
| $2.34M | 1.09% | 2.71% | -13.0% | Q4 2021 | |
| $2.33M | 1.08% | 1.32% | +103.4% | Q4 2024 | |
| $2.16M | 1.00% | 0.03% | +13.3% | Q1 2024 | |
| $2.03M | 0.94% | 0.10% | +7.1% | Q1 2025 | |
| $1.85M | 0.86% | 0.05% | Not reported | Q4 2021 | |
| AACLXArcellx, Inc. | $1.68M | 0.78% | 0.04% | Not reported | Q1 2023 |
| $1.54M | 0.71% | 0.39% | Not reported | Q1 2025 | |
| $1.53M | 0.71% | 0.05% | Not reported | Q1 2025 | |
| $1.43M | 0.66% | 0.00% | Not reported | Q4 2021 | |
| $1.34M | 0.62% | 0.03% | Not reported | Q4 2021 | |
| $1.32M | 0.61% | 0.04% | Not reported | Q1 2025 | |
| $1.25M | 0.58% | 0.08% | Not reported | Q1 2022 | |
| $1.19M | 0.55% | 0.00% | -18.5% | Q4 2021 | |
| $1.16M | 0.54% | 0.01% | Not reported | Q3 2022 | |
| $1.1M | 0.51% | 0.03% | Not reported | Q4 2021 | |
| $1.06M | 0.49% | 0.00% | +200.0% | Q3 2025 | |
| $1.04M | 0.48% | 0.44% | +28.2% | Q2 2025 | |
| $916K | 0.42% | 0.21% | Not reported | Q1 2025 | |
| $860K | 0.40% | 0.17% | -34.5% | Q2 2025 | |
| $805K | 0.37% | 0.00% | -56.6% | Q4 2021 | |
| $802K | 0.37% | 0.36% | +23.6% | Q3 2025 | |
| $774K | 0.36% | 0.00% | Not reported | Q4 2021 | |
| $678K | 0.31% | 0.00% | Not reported | Q4 2021 | |
| $661K | 0.31% | 0.15% | Not reported | Q1 2023 | |
| $655K | 0.30% | 0.08% | New | Q4 2025 | |
| $634K | 0.29% | 0.00% | Not reported | Q1 2023 | |
| $613K | 0.28% | 0.01% | +54.6% | Q3 2025 | |
| $598K | 0.28% | 0.60% | +215.5% | Q3 2025 | |
| $569K | 0.26% | 0.00% | Not reported | Q4 2021 | |
| $564K | 0.26% | 0.35% | New | Q4 2025 | |
| $491K | 0.23% | 0.01% | Not reported | Q4 2021 | |
| $490K | 0.23% | 0.03% | New | Q4 2025 | |
| $460K | 0.21% | 0.02% | -61.5% | Q1 2025 | |
| MTMRSNMersana Therapeutics, Inc. | $438K | 0.20% | 2.23% | New | Q4 2025 |
| $407K | 0.19% | 0.04% | -41.7% | Q2 2024 | |
| $359K | 0.17% | 0.32% | Not reported | Q3 2025 | |
| Q3 2025Reported Nov 12, 202582 positions | |||||
| $51.6M | 20.79% | 3.26% | -13.7% | Q4 2021 | |
| $30M | 12.09% | 0.04% | Not reported | Q4 2021 | |
| $27.3M | 11.02% | Not reported | Not reported | Q4 2021 | |
| $8.26M | 3.33% | 0.61% | -4.3% | Q4 2023 | |
| $6.58M | 2.66% | 0.49% | +21.3% | Q1 2024 | |
| $6.43M | 2.59% | 0.00% | -2.9% | Q4 2021 | |
| $6.21M | 2.51% | 0.29% | Not reported | Q3 2023 | |
| APAVDLAvadel Pharmaceuticals PLC | $5.54M | 2.24% | 0.37% | -14.8% | Q4 2021 |
| $5.51M | 2.22% | 0.13% | +3.8% | Q3 2023 | |
| $4.41M | 1.78% | 0.04% | +6.3% | Q1 2022 | |
| $4.18M | 1.68% | 3.14% | Not reported | Q4 2021 | |
| VPVRNAVerona Pharma plc | $4.09M | 1.65% | 0.01% | -30.3% | Q4 2023 |
| $3.82M | 1.54% | 0.29% | Not reported | Q2 2025 | |
| CPCPRXCatalyst Pharmaceuticals, Inc. | $3.72M | 1.50% | 0.15% | +7.4% | Q4 2023 |
| $2.59M | 1.04% | 0.30% | New | Q3 2025 | |
| $2.52M | 1.01% | 0.14% | +27.4% | Q4 2024 | |
| $2.48M | 1.00% | 0.00% | Not reported | Q1 2023 | |
| $2.45M | 0.99% | 0.12% | +19.8% | Q4 2021 | |
| AACLXArcellx, Inc. | $2.11M | 0.85% | 0.04% | Not reported | Q1 2023 |
| $1.9M | 0.77% | 0.00% | Not reported | Q4 2021 | |
| $1.83M | 0.74% | 0.05% | Not reported | Q4 2021 | |
| $1.69M | 0.68% | 0.10% | +3.4% | Q1 2025 | |
| $1.65M | 0.66% | 0.03% | Not reported | Q1 2024 | |
| $1.56M | 0.63% | 0.05% | Not reported | Q1 2025 | |
| $1.48M | 0.60% | 0.13% | New | Q3 2025 | |
| $1.29M | 0.52% | 0.09% | +36.0% | Q1 2025 | |
| $1.28M | 0.52% | 0.00% | Not reported | Q4 2021 | |
| $1.22M | 0.49% | 0.00% | Not reported | Q4 2021 | |
| $1.17M | 0.47% | 0.00% | Not reported | Q4 2021 | |
| $1.16M | 0.47% | 0.40% | Not reported | Q1 2025 | |
| $1.08M | 0.43% | 0.02% | Not reported | Q4 2021 | |
| $1M | 0.40% | 0.21% | Not reported | Q1 2025 | |
| DODAWNDay One Biopharmaceuticals, Inc. | $920K | 0.37% | 0.13% | +287.1% | Q2 2025 |
| $917K | 0.37% | 0.01% | Not reported | Q3 2022 | |
| $829K | 0.33% | 0.00% | Not reported | Q4 2021 | |
| $826K | 0.33% | 0.65% | +109.7% | Q4 2024 | |
| $756K | 0.30% | 0.04% | +30.0% | Q1 2025 | |
| $747K | 0.30% | 0.00% | Not reported | Q4 2021 | |
| $746K | 0.30% | 0.00% | Not reported | Q4 2021 | |
| $734K | 0.30% | 0.00% | Not reported | Q4 2021 | |
| $659K | 0.27% | 0.06% | +125.0% | Q1 2025 | |
| $635K | 0.26% | 0.00% | Not reported | Q4 2021 | |
| $619K | 0.25% | 0.04% | -6.0% | Q1 2024 | |
| $604K | 0.24% | 0.00% | Not reported | Q1 2023 | |
| $596K | 0.24% | 0.08% | Not reported | Q2 2024 | |
| $579K | 0.23% | 0.01% | -60.6% | Q2 2023 | |
| $537K | 0.22% | 0.00% | Not reported | Q4 2021 | |
| $500K | 0.20% | 0.00% | Not reported | Q4 2021 | |
| $484K | 0.20% | 0.35% | +95.0% | Q2 2025 | |
| $460K | 0.19% | 0.32% | New | Q3 2025 | |
Premium opens every quarter this fund has filed